ArticleJournal of cellular and molecular medicine2022
Vasorin deficiency leads to cardiac hypertrophy by targeting MYL7 in young mice.
Article in Journal of cellular and molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Proteomic Remodeling in the Failing Left Ventricle Adapting to Dyssynchrony.Proteomics. Clinical applications · 2026Article
- Article
- The Network of Exosomes miRNA and p-MLC2 Regulatory Pathway Induced Pathological Cardiac Hypertrophy in Vasn Deficient Mice.Journal of cellular and molecular medicine · 2025Article
- VASN drives gastric tumorigenesis via activation of the COL4A1/PI3K/AKT axis during Helicobacter pylori infection.British journal of cancer · 2025Article
- Decreased Extracellular Vesicle Vasorin in Severe Preeclampsia Plasma Mediates Endothelial Dysfunction.Journal of the American Heart Association · 2025Article
- An Exploratory Study of Serum Vasorin Levels in Polycystic Ovary Syndrome: A Novel Potential Biomarker for Diagnosis and Pathogenesis.Metabolites · 2025Article
- Vasorin-deficient mice display disturbed vitamin D and mineral homeostasis in combination with a low bone mass phenotype.Bone reports · 2024Article
- Enhanced vasorin signaling mitigates adverse cardiovascular remodeling.Aging medicine (Milton (N.S.W)) · 2024Review
- Single-cell RNA sequencing reveals the transcriptional heterogeneity of Tbx18-positive cardiac cells during heart development.Functional & integrative genomics · 2024Article
- VASN knockout induces myocardial fibrosis in mice by downregulating non-collagen fibers and promoting inflammation.Frontiers in pharmacology · 2024Article
- Vasorin contributes to lung injury via FABP4-mediated inflammation.Molecular biology reports · 2022Article
- Vasorin plays a critical role in vascular smooth muscle cells and arterial functions.Journal of cellular physiology · 2022Article
- Vasorin Deletion in C57BL/6J Mice Induces Hepatocyte Autophagy through Glycogen-Mediated mTOR Regulation.Nutrients · 2022Article
- Inhibition of activin A receptor signalling attenuates age-related pathological cardiac remodelling.Disease models & mechanisms · 2022Article
- Vasorin deficiency leads to cardiac hypertrophy by targeting MYL7 in young mice.Journal of cellular and molecular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vasorin (VASN) is an important transmembrane protein associated with development and disease. However, it is not clear whether the death of mice with VASN deficiency (VASN
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.